PERSPECTA

News from every angle

← Back to headlines

ImmunityBio Skyrockets on Anktiva-Driven Revenue Jump

ImmunityBio (IBRX) stock has surged significantly after its drug Anktiva propelled a 671% increase in revenue.

25 Feb, 06:44 — 25 Feb, 06:44
PostShare

Sources

Showing 1 of 1 sources
YahooMostly Factual45d ago

ImmunityBio (IBRX) Skyrockets as Anktiva Propels 671% Revenue Jump

Read full article →

Related Stories

Amazon's First Customer Receipt Goes Viral, Bezos and Musk React

just now

Four Arrested for Selling P102 Million in Counterfeit Anti-Cancer Medicine in Makati

15m ago

Japan to Improve Treatment of Technical Staff in Research Institutions

25m ago

Ethiopian Factory Transforms Old Tires into Shoes

28m ago